Sugi Predict

Sugi Predict / Compounds / SCHEMBL1976780

SCHEMBL1976780

SCHEMBL1976780

CCOC(=O)c1sc(Br)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 3/20 0.58
▸ RAB9A P51151 12/20 0.54
▸ SMN1; SMN2 Q16637 12/20 0.54
▸ NPC1 O15118 11/20 0.54
▸ HTT P42858 2/20 0.54
▸ TP53 P04637 5/20 0.51
▸ MAPT P10636 12/20 0.51
▸ KMT2A Q03164 12/20 0.51
▸ MEN1 O00255 11/20 0.51
▸ ALDH1A1 P00352 8/20 0.51
▸ HPGD P15428 7/20 0.51
▸ KDM4E B2RXH2 7/20 0.51
▸ HSD17B10 Q99714 4/20 0.51
▸ NFKB1 P19838 3/20 0.50
▸ NFKB2 Q00653 3/20 0.50
▸ RELA Q04206 3/20 0.50
▸ LMNA P02545 4/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ PKM P14618 1/20 0.49
▸ STAT1 P42224 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12483440 0.86 GSK3B (0.53) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL2028240 0.85 ALOX15 (0.61) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL1531268 0.83 MAPT (0.63) ALOX15RAB9ASMN1; SMN2NPC1TP53
SCHEMBL2730725 0.81 MAPT (0.44) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL15962456 0.81 ALOX15 (0.47) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL244336 0.79 ALOX15 (0.58) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL26281541 0.79 ALOX15 (0.58) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL27602779 0.78 GSK3B (0.47) ALOX15RAB9ASMN1; SMN2NPC1HTT
SCHEMBL20263505 0.77 NPC1 (0.39) ALOX15RAB9ASMN1; SMN2NPC1HTT
Hydrochloric Acid SCHEMBL244320 0.77 ALOX15 (0.56) ALOX15RAB9ASMN1; SMN2NPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116023359-B Synthesis method of aminothiophene compound and aminothiophene compound 上海泰坦科技股份有限公司 2024-08-02 — — CN disclosed
CN-116023359-A Synthesis method of aminothiophene compound and aminothiophene compound 上海泰坦科技股份有限公司 2023-04-28 — — CN disclosed
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 — — US disclosed
US-20150065343-A1 Acrylamide compounds for combating invertebrate pests BASF SE (DE) 2015-03-05 — — US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 — — US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 — — US disclosed
US-20140024583-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2014-01-23 — — US disclosed
WO-2013149940-A1 ACRYLAMIDE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS BASF SE (DE) 2013-10-10 — — WO disclosed
US-8501746-B2 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2013-08-06 — — US disclosed
US-8258160-B2 SCD1 inhibitors triazole and tetrazole compounds NOVARTIS AG (CH) 2012-09-04 — — US disclosed
US-20090156615-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-06-18 — — US disclosed
EP-2029572-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-03-04 — — EP disclosed
WO-2008074835-A1 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS NOVARTIS AG (CH) 2008-06-26 — — WO disclosed
CN-101166745-A Thienopyridine compounds and methods of use thereof FIBROGEN INC (US) 2008-04-23 — — CN disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 — — EP disclosed
WO-2007143597-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-12-13 — — WO disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 — — WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 — — US disclosed
US-20050256124-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto NEUROCRINE BIOSCIENCES, INC. (US) 2005-11-17 — — US disclosed
WO-2005103039-A1 2- (3-AMINOPYRROLIDIN-1-YL) PYRIDINES AS MELANIN-CONCENTRATING HORMONE RECEPTOR AN TAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2005-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 ALOX15 1740/4885RAB9A 4193/4885SMN1; SMN2 2645/4885
US-20090156615-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 ALOX15 110/4885RAB9A 4305/4885SMN1; SMN2 3581/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 ALOX15 1740/4885RAB9A 4193/4885SMN1; SMN2 2645/4885
US-20150065343-A1 Acrylamide compounds for combating invertebrate pests AAAS, ACR, ATL3 ALOX15 1869/4885RAB9A 3855/4885SMN1; SMN2 2155/4885
US-20140024583-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 ALOX15 110/4885RAB9A 4305/4885SMN1; SMN2 3581/4885
US-20050256124-A1 Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto MCHR1, MCHR2, MC1R ALOX15 345/4885RAB9A 2176/4885SMN1; SMN2 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.